Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248896 | 0.86 | ADORA3 (0.68) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728476 | 0.83 | LMNA (0.65) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL26884353 | 0.81 | LMNA (0.62) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728560 | 0.81 | MEN1 (0.62) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728481 | 0.80 | LMNA (0.64) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728556 | 0.80 | KDM4E (0.67) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728498 | 0.80 | LMNA (0.78) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728558 | 0.80 | MPL (0.69) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL235190 | 0.79 | KDM4E (0.70) | LMNAKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL22728479 | 0.79 | LMNA (0.60) | LMNAKDM4ESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420964-B2 | Compositions and methods for modulating inflammatory and degenerative disorder | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220048901-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-17 | — | — | US | disclosed |
| US-20200377494-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420964-B2 | Compositions and methods for modulating inflammatory and degenerative disorder | TNF, MSR1, GRN | LMNA 1893/4885KDM4E 4725/4885SMN1; SMN2 1011/4885 |
| US-20220048901-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | TNF, MSR1, GRN | LMNA 1893/4885KDM4E 4725/4885SMN1; SMN2 1011/4885 |
| US-20200377494-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | TNF, MSR1, GRN | LMNA 1893/4885KDM4E 4725/4885SMN1; SMN2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.